Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Attia

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.
Rare Tumors|August 13, 2015
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing SarcomaSteven Attia, Scott H Okuno, Steven I Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS StudySebastian Bauer, Michael C Heinrich, Suzanne George, et al.
JAMA Oncology|March 31, 2022
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical TrialRobin L Jones, Vinod Ravi, Andrew S Brohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2025
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi TrialRavin Ratan, Bernd Kasper, Thierry Alcindor, et al.
Cancer Medicine|August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial resultsSteven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
The Lancet. Oncology|June 9, 2020
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean-Yves Blay, César Serrano, Michael C Heinrich, et al.
Rare Tumors|August 13, 2015
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing SarcomaSteven Attia, Scott H Okuno, Steven I Robinson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS StudySebastian Bauer, Michael C Heinrich, Suzanne George, et al.
JAMA Oncology|March 31, 2022
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical TrialRobin L Jones, Vinod Ravi, Andrew S Brohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2025
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi TrialRavin Ratan, Bernd Kasper, Thierry Alcindor, et al.
Cancer Medicine|August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial resultsSteven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Pageof 8